AURX

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Jorden David EmersonDirector, Officer: CEO/CFO --13.2k shares Grant / ExerciseJun 5, 2026 $14.5K13.2k shares $1.10 $1.07
Pittman Scott M.Director, 10 Percent Owner: --36.8k shares OtherMay 29, 2026 $55.1K36.8k shares $1.50 $1.07
Pittman Scott M.Director, 10 Percent Owner: --17.5k shares Grant / ExerciseMay 29, 2026 $26.3K17.5k shares $1.50 $1.07
Pittman Scott M.Director, 10 Percent Owner: --17.5k shares Grant / ExerciseMay 29, 2026 $26.2K17.5k shares $1.50 $1.07
Pittman Scott M.Director, 10 Percent Owner: --7.5k shares OtherMay 29, 2026 $11.3K7.5k shares $1.50 $1.07
Pittman Scott M.Director, 10 Percent Owner: --7.3k shares Grant / ExerciseMay 29, 2026 $11.0K7.3k shares $1.50 $1.07

News

globenewswire.comNuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 14

Trade AURX

About Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.

CEO: David E. Jorden
IPO Date: Oct 24, 2017

Market Data

Open: $1.02
High: $1.02
Low: $1.00
Volume: 0
52W High: $3.23
52W Low: $0.8415

Valuation

Market Cap: $48M
Enterprise Value: $49M

Financials

Free Cash Flow: $-1.1M
Revenue: $3.3M
Net Income: $-2.5M
Cash: $549k
Debt: $97k

Events

EarningsJun 29

EPS est. -0.01